

3. Danckaerts M, Sonuga-Barke EJ, Banaschewski T et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. *Eur Child Adolesc Psychiatry* 2010;19:83–105
4. Agarwal R, Goldenberg M, Perry R et al. The quality of life of adults with attention deficit hyperactivity disorder: a systematic review. *Innov Clin Neurosci* 2012;9:10–21
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). Washington, DC: American Psychiatric Publishing, 2013
6. World Health Organization. International Classification of Diseases for mortality and morbidity statistics (ICD-11) 2018; <http://icd.who.int>
7. Reed GM, First MB, Kogan CS et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. *World Psychiatry* 2019; 8:3–19
8. Epstein JN, Loren RE. Changes in the Definition of ADHD in DSM-5: Subtle but Important. *Neuropsychiatry (London)* 2013;3:455–8
9. Polanczyk GV, Willcutt EG, Salum GA, Kielling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. *Int J Epidemiol* 2014;43:434–42
10. Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. *Pediatrics* 2015;135:e994–1001
11. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. *Br J Psychiatry* 2009;194: 204–11
12. Parr JW. Attention-deficit hyperactivity disorder and the athlete: new advances and understanding. *Clin Sports Med* 2011;30:591–610
13. Poyssophon P, Rao AL. Neurocognitive Deficits Associated With ADHD in Athletes: a Systematic Review. *Sports Health* 2018;10:317–26
14. Zierys S, Jansen P. Effects of physical activity on executive function and motor performance in children with ADHD. *Res Dev Disabil* 2015;38:181–91
15. White RD, Harris GD, Gibson ME. Attention deficit hyperactivity disorder and athletes. *Sports Health* 2014;6:149–56
16. Lebrun F, MacNamara A, Rodgers S et al. Learning From Elite Athletes' Experience of Depression. *Front Psychol* 2018;9:2062
17. Stewman CG, Liebman C, Fink L et al. Attention Deficit Hyperactivity Disorder: Unique Considerations in Athletes. *Sports Health* 2018;10:40–6
18. Hoza B, Martin CP, Pirog A et al. Using Physical Activity to Manage ADHD Symptoms: The State of the Evidence. *Curr Psychiatry Rep* 2016;18:113
19. Kiluk BD, Weden S, Culotta VP. Sport participation and anxiety in children with ADHD. *J Atten Disord* 2009;12:499–506
20. Pujalte GGA, Maynard JR, Thurston MJ et al. Considerations in the Care of Athletes With Attention Deficit Hyperactivity Disorder. *Clin J Sport Med* 2019;29:245–56
21. Conant-Norville DO, Tofter IR. Attention deficit/hyperactivity disorder and psychopharmacologic treatments in the athlete. *Clin Sports Med* 2005;24:829–43, viii
22. Perroud N, Hasler R, Golay N et al. Personality profiles in adults with attention deficit hyperactivity disorder (ADHD). *BMC Psychiatry* 2016;16:199
23. Excellence NifHaC. Attention deficit hyperactivity disorder: diagnosis and management. London, 14 March 2018 Last updated: 13 September 2019;
24. Cortese S, Adamo N, Del Giovane C et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry* 2018;5:727–38
25. Reardon CL, Factor RM. Considerations in the Use of Stimulants in Sport. *Sports Med* 2016;46:611–7
26. Smith GM, Beecher HK. Amphetamine sulfate and athletic performance. I. Objective effects. *J Am Med Assoc* 1959;170:542–57
27. Chandler JV, Blair SN. The effect of amphetamines on selected physiological components related to athletic success. *Med Sci Sports Exerc* 1980;12:65–9
28. Roelands B, Hasegawa H, Watson P et al. The effects of acute dopamine reuptake inhibition on performance. *Med Sci Sports Exerc* 2008;40:879–85
29. Watson P, Hasegawa H, Roelands B et al. Acute dopamine/noradrenaline reuptake inhibition enhances human exercise performance in warm, but not temperate conditions. *J Physiol* 2005;565:873–83
30. Han DH, McDuff D, Thompson D et al. Attention-deficit/hyperactivity disorder in elite athletes: a narrative review. *Br J Sports Med* 2019;53:741–5
31. Punja S, Shamseer L, Hartling et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database Syst Rev* 2016;2:CD009996
32. Vetter VL, Elia J, Erickson C et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. *Circulation* 2008;117:2407–23
33. Liu H, Feng W, Zhang D. Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis. *Eur Child Adolesc Psychiatry* 2019;28:1283–93
34. Perrin JM, Friedman RA, Nilans TK et al. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. *Pediatrics* 2008;122:451–3
35. Ciocca M. Attention Deficit Hyperactivity Disorder in Athletes. *Clin Sports Med* 2019;38:545–54
36. Roelands B, Hasegawa H, Watson P et al. Performance and thermoregulatory effects of chronic bupropion administration in the heat. *Eur J Appl Physiol* 2009;105:493–8
37. Reardon CL, Creado S. Psychiatric medication preferences of sports psychiatrists. *Phys Sportsmed* 2016;44:397–402
38. Navarra R, Graf R, Huang Y et al. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 2008;32:34–41
39. Reardon CL. The sports psychiatrist and psychiatric medication. *Int Rev Psychiatry* 2016;28:606–13
40. Garner AA, Hansen AA, Baxley C et al. The Use of Stimulant Medication to Treat Attention-Deficit/Hyperactivity Disorder in Elite Athletes: A Performance and Health Perspective. *Sports Med* 2018;48:507–12



**Dr. med. Xaver Berg**  
 Sportpsychiatrie und  
 -psychotherapie, Klinik für  
 Psychiatrie, Psychotherapie  
 und Psychosomatik,  
 Psychiatrische Universitätsklinik  
 Zürich,  
 Lenggstrasse 31,  
 CH-8032 Zürich  
 E-Mail: [xaver.berg@pukzh.ch](mailto:xaver.berg@pukzh.ch)



**Dr. med. Malte Claussen**  
 Sportpsychiatrie und  
 -psychotherapie, Klinik für  
 Psychiatrie, Psychotherapie  
 und Psychosomatik,  
 Psychiatrische Universitätsklinik  
 Zürich;  
 Privatklinik Wyss AG;  
 Psychiatrische Dienste  
 Graubünden

### Erratum

Erratum zu: Schizophrenie – Indikationen für Depotneuroleptika

Ion-George Anghelescu, Berlin

DNP – Der Neurologe & Psychiater 2020;21(4): 22–30

Auf S. 29, 2. Absatz, wurde im vorletzten Satz der Zeitpunkt der zweiten Initiationsdosis des Einmonatsdepotpräparats Paliperidonpalmitat nicht korrekt angegeben. Richtig muss es heißen: „Die zweite Initiationsdosis kann also zwischen vier und zwölf Tagen nach der ersten gegeben werden.“

Wir bitten diesen Fehler zu entschuldigen.

Die Redaktion

Die Online-Version des Originalartikels ist unter <https://doi.org/10.1007/s15202-020-2862-8> zu finden.